Hormonal management of prostate cancer.
In advanced disease, androgen deprivation remains the usual treatment. The completion of current trials is awaited to confirm whether total androgen blockade will prolong survival. To make further advances in treatment the fundamental biology of the prostate cell, benign or malignant, and its relationship to endocrine manipulation, must be understood. This may then lead to an understanding of clonal escape mechanisms in transformed cells and the clinical correlate of escape, relapse.
Wasan
H S
HS
Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Waxman
J
J
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D012739:Gonadal Steroid Hormones / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D000726:Androgen Antagonists; D012739:Gonadal Steroid Hormones